Get App
Corona Remedies IPO is a bookbuilt issue of Rs 655.37 crore. This issue is entirely an offer for sale of 0.62 crore shares with no fresh issue.
The IPO opens for subscription on December 8, 2025 and closes on December 10. The allotment is expected to be finalized on Thursday, December 11, 2025. The price band for the IPO is set at ₹1008 to ₹1062 per share, and the minimum lot size for an application is 14 shares.
Company Summary
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.
Company Strengths
- Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
- Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
- Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
- Qualified, experienced and entrepreneurial management team supported by marquee investors.
Company Financials
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.1 |
| Profit After Tax | 46.2 | 149.43 | 90.5 | 84.93 |
| EBITDA | 71.8 | 245.91 | 161.19 | 135.03 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.7 | 134.14 | 2.33 |
| Amount in ₹ Crore | ||||
Objectives of IPO
Corona Remedies itself will not receive any proceeds from the IPO. Instead, the entire proceeds, net of offer-related expenses, will go to the selling shareholder.
Promorters of the company
The company’s promoters are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
IPO Details
| IPO Date | December 8, 2025 to December 10, 2025 |
| Listing Date | December 15, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹1008 to ₹1062 per share |
| Lot size | 14 shares |
| Total Issue size | 61,71,101 shares (aggregating upto ₹655.37 Cr ) |
| Issue type | Bookbuilding IPO |
| Listing at | NSE, BSE |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
Category Reservation Table
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
| Only RII | Upto Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII | 1. Employee limit: (In certain cases, employees are given discount if bidding amount is upto Rs 2 Lakhs) 2. If applying as RII: Upto Rs 2 Lakhs 3. If applying as NII: sNII > Rs 2 Lakhs and upto Rs 10 Lakhs and bNII > Rs 10 lakhs | Yes for Employee and RII/NII |
Lot Allocation Details
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 14 | ₹14,868.00 |
| Retail (Max) | 13 | 182 | ₹1,93,284.00 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152.00 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156.00 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024.00 |
Allotment Schedule
| Basis of Allotment | Thu, 11 Dec, 2025 |
| Initiation of Refunds | Fri, 12 Dec, 2025 |
| Credit of Shares to Demat | Fri, 12 Dec, 2025 |
| Tentative Listing Date | Mon, 15 Dec, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 10, 2025 |
IPO Reservation
| Investor Category | Shares Offered |
| QIB Shares Offered | Not less than 50% of the Net Offer |
| Retail Shares Offered | Not more than 35% of the Net Offer |
| NII Shares Offered | Not more than 15% of the Net Offer |
To check allotment, click here
Download NOVO App!
Invest in Zero-commission Direct Mutual funds, IPO, Sovereign Gold bonds, Government bills, and Corporate bonds.
